These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15156302)

  • 21. Plasma nevirapine concentrations predict virological and adherence failure in Kenyan HIV-1 infected patients with extensive antiretroviral treatment exposure.
    Kimulwo MJ; Okendo J; Aman RA; Ogutu BR; Kokwaro GO; Ochieng DJ; Muigai AW; Oloo FA; Ochieng W
    PLoS One; 2017; 12(2):e0172960. PubMed ID: 28235021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
    Heil SG; van der Ende ME; Schenk PW; van der Heiden I; Lindemans J; Burger D; van Schaik RH
    Ther Drug Monit; 2012 Apr; 34(2):153-9. PubMed ID: 22354160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis.
    Matteelli A; Saleri N; Villani P; Bonkoungou V; Carvalho AC; Kouanda S; Sanou MJ; Simporé J; Monno L; Carosi G; Regazzi M; Dembele M
    J Acquir Immune Defic Syndr; 2009 Sep; 52(1):64-9. PubMed ID: 19731452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatotoxicity in patients prescribed efavirenz or nevirapine.
    Brück S; Witte S; Brust J; Schuster D; Mosthaf F; Procaccianti M; Rump JA; Klinker H; Petzold D; Hartmann M
    Eur J Med Res; 2008 Jul; 13(7):343-8. PubMed ID: 18700192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics of nevirapine in Thai HIV-infected patients.
    Wattanakul T; Avihingsanon A; Manosuthi W; Punyawudho B
    Antivir Ther; 2014; 19(7):651-60. PubMed ID: 24504545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.
    Manosuthi W; Athichathanabadi C; Uttayamakul S; Phoorisri T; Sungkanuparph S
    BMC Infect Dis; 2007 Mar; 7():14. PubMed ID: 17352798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.
    Dickinson L; Chaponda M; Carr DF; van Oosterhout JJ; Kumwenda J; Lalloo DG; Pirmohamed M; Heyderman RS; Khoo SH
    Antimicrob Agents Chemother; 2014; 58(2):706-12. PubMed ID: 24217698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
    Leth FV; Kappelhoff BS; Johnson D; Losso MH; Boron-Kaczmarska A; Saag MS; Livrozet JM; Hall DB; Leith J; Huitema AD; Wit FW; Beijnen JH; Lange JM;
    AIDS Res Hum Retroviruses; 2006 Mar; 22(3):232-9. PubMed ID: 16545009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.
    Sanne I; Mommeja-Marin H; Hinkle J; Bartlett JA; Lederman MM; Maartens G; Wakeford C; Shaw A; Quinn J; Gish RG; Rousseau F
    J Infect Dis; 2005 Mar; 191(6):825-9. PubMed ID: 15717255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
    Moltó J; Valle M; Miranda C; Cedeño S; Miranda J; Santos JR; Negredo E; Vilaró J; Costa J; Clotet B
    J Antimicrob Chemother; 2008 Oct; 62(4):784-92. PubMed ID: 18593723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
    Arasteh K; Ward D; Plettenberg A; Livrozet JM; Orkin C; Cordes C; Guo J; Wang E; Yong CL; Robinson P; Quinson A
    HIV Med; 2012 Apr; 13(4):236-44. PubMed ID: 22136068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evidence-based therapeutic drug monitoring for nevirapine].
    Muret P; Piedoux S; Solas C; Quaranta S;
    Therapie; 2011; 66(3):187-95. PubMed ID: 21819802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals.
    Ouyang DW; Brogly SB; Lu M; Shapiro DE; Hershow RC; French AL; Leighty RM; Thompson B; Tuomala RE
    AIDS; 2010 Jan; 24(1):109-14. PubMed ID: 19926957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.
    Baroncelli S; Villani P; Floridia M; Pirillo MF; Galluzzo CM; Cusato M; Amici R; Pinnetti C; Sabbatini F; Molinari A; Tamburrini E; Regazzi M
    Ther Drug Monit; 2008 Oct; 30(5):604-10. PubMed ID: 18728627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
    Baxi SM; Greenblatt RM; Bacchetti P; Jin C; French AL; Keller MJ; Augenbraun MH; Gange SJ; Liu C; Mack WJ; Gandhi M;
    PLoS One; 2015; 10(6):e0129100. PubMed ID: 26053176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nevirapine prophylaxis to prevent HIV-1 mother-to-child transmission: pharmacokinetic considerations in preterm infants.
    Capretti MG; Marsico C; Conti M; Corvaglia LT; Arcuri S; Faldella G; Re MC
    New Microbiol; 2016 Oct; 39(4):314-316. PubMed ID: 27284987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
    Saitoh A; Sarles E; Capparelli E; Aweeka F; Kovacs A; Burchett SK; Wiznia A; Nachman S; Fenton T; Spector SA
    AIDS; 2007 Oct; 21(16):2191-9. PubMed ID: 18090046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma.
    van Praag RM; Repping S; de Vries JW; Lange JM; Hoetelmans RM; Prins JM
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2902-7. PubMed ID: 11557488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study.
    Giaquinto C; Anabwani G; Feiterna-Sperling C; Nuttall J; Mompati K; Königs C; Mensa FJ; Sabo JP; Yong CL; MacGregor TR; Nguyen T; Quinson AM
    Pediatr Infect Dis J; 2014 Jul; 33(7):e173-9. PubMed ID: 24378938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach.
    Dailly E; Raffi F; Perré P; Martin J; Deslandes G; Jolliet P
    HIV Med; 2009 Oct; 10(9):586-9. PubMed ID: 19486187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.